大黄蟅虫胶囊联合恩替卡韦治疗慢性乙型肝炎肝纤维化的效果观察

谢永财; 胡国信; 彭雁忠; 郑洁; 李银平

doi:10.3969/j.issn.1001-5256.2016.08.014

大黄蟅虫胶囊联合恩替卡韦治疗慢性乙型肝炎肝纤维化的效果观察

DOI: 10.3969/j.issn.1001-5256.2016.08.014

1. 广州医科大学
2. 北京大学深圳医院感染科
3. 深圳市石岩人民医院
4. 北京大学深圳医院中医科

基金项目:

国家自然科学基金资助项目(81473473)；深圳市科技计划项目(JCYJ20140415162543026)；

详细信息

中图分类号: R512.62;R575.2
计量
- 文章访问数: 2082
- HTML全文浏览量: 28
- PDF下载量: 455
- 被引次数: 0
出版历程
- 出版日期: 2016-08-20

Clinical effect of Dahuang Zhechong capsules combined with entecavir in treatment of chronic hepatitis B patients with liver fibrosis

Guangzhou Medical University

Research funding:

摘要

摘要:
目的观察大黄蟅虫胶囊联合恩替卡韦治疗慢性乙型肝炎肝纤维化的临床疗效。方法收集2014年10月-2016年1月于北京大学深圳医院门诊和住院治疗的慢性乙型肝炎肝纤维化患者100例。将患者随机分为2组,每组各50例,其中西药组采用恩替卡韦治疗,联合治疗组在西药组的基础上加服大黄蟅虫胶囊治疗,疗程均为48周。观察两组患者肝功能、HBV DNA载量、血清肝纤维化4项、肝脏硬度、天门冬氨酸氨基转移酶-血小板指数（APRI）/肝纤维化指数（Fibro Index）变化情况。计量资料组间比较采用t检验,计数资料组间比较采用χ2检验。结果与同组治疗前相比,治疗48周后两组患者肝功能ALT、AST和HBV DNA载量均下降,差异均有统计学意义（P值均<0.05）。两组患者治疗后肝纤纤维化4项均恢复正常,且两组间血清透明质酸、Ⅲ型前胶原、Ⅳ型胶原水平比较,差异均有统计学意义（P值均<0.05）。治疗后两组间比较,门静脉内径、脾厚度、肝硬度值和APRI/FibroIndex指数。差异均有统计学意义（P值均<0.05）。联合治疗组治疗总有效率（92.0%）高于西药组（72.0%）,差异有统计学...
- 肝炎,乙型,慢性 /
- 肝硬化 /
- 大黄蟅虫丸 /
- 恩替卡韦 /
- 治疗
Abstract:
Objective To investigate the clinical effect of Dahuang Zhechong capsules combined with entecavir in the treatment of chronic hepatitis B( CHB) patients with liver fibrosis. Methods A total of 100 CHB patients with liver fibrosis who visited or were hospitalized in Shenzhen Hospital of Peking University from October 2014 to January 2016 were enrolled and randomly divided into Western medicine group and combined treatment group,with 50 patients in each group. The patients in the Western medicine group were given entecavir,and those in the combined treatment group were given Dahuang Zhechong capsules in addition to entecavir. The course of the treatment was 48 weeks.The changes in liver function,HBV DNA load,four serum parameters of liver fibrosis,liver stiffness,and aspartate aminotransferase- to-platelet ratio index( APRI) / Fibro Index were observed in both groups. The t- test was used for comparison of continuous data between groups,and the chi- square test was used for comparison of categorical data between groups. Results Both groups showed significant reductions in serum levels of aspartate aminotransferase( AST),alanine aminotransferase( ALT),and HBV DNA load after 48 weeks of treatment( all P < 0. 05). After treatment,the four serum parameters of liver fibrosis all returned to normal after treatment,and the serum levels of hyaluronic acid,type Ⅲ precollagen,and type IV collagen showed significant differences between the two groups( all P < 0. 05),and the portal vein diameter,thickness of the spleen,liver stiffness and APRI / Fibro Index also showed significant differences between the two groups( both P < 0. 05). The combined treatment group had a significantly higher overall response rate than the Western medicine group( 92. 0%vs 72. 0%,χ2= 6. 775,P = 0. 009). Conclusion Dahuang Zhechong capsules combined with entecavir have a better effect in the treatment of CHB patients with liver fibrosis compared with entecavir alone.
- hepatitis B /
- chronic /
- liver cirrhosis /
- DAHUANG ZHECHONG PILL /
- entecavir

HTML全文

参考文献(16)

[1]XIE YC,HU GX.Current status of clinical and experimental studies on Dahuang Zhechong pills in liver disease[J].Chin J Integr Tradit West Med Dig,2015,23(12):905-910.(in Chinese)谢永财,胡国信.大黄蟅虫丸在肝病领域中的临床与实验研究现状[J].中国中西医结合消化杂志,2015,23(12):905-910.

[2] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].Chin J Infect Dis,2011,29(2):65-80.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].中华传染病杂志,2011,29(2):65-80..

[3]Liver Disease Committee,Chinese Association of Integrative Medicine.Guidelines for the diagnosis and treatment of liver fibrosis in integrative medicine practice[J].Chin J Hepatol,2006,14(11):866-870.(in Chinese)中国中西医结合学会肝病专业委员会.肝纤维化中西医结合诊疗指南[J].中华肝脏病杂志,2006,14(11):866-870.

[4]ZHANG RF,YAO YJ,YOU ZL,et al.Clinical effect observation of compound turtle shell soft liver pills combined with entecavir in treatment of liver fibrosis with chronic hepatitis B[J].J Third Milit Med Univ,2014,36(18):1961-1963.(in Chinese)张瑞凤,姚云洁,游忠岚,等.复方鳖甲软肝片联合恩替卡韦治疗慢性乙型肝炎肝纤维化的观察[J].第三军医大学学报,2014,36(18):1961-1963.

[5]LIAN J,HAN T,XIANG HL,et al.A randomized controlled trial on 240-week monotherapy with entecavir or adefovir in patients with chronic hepatitis B and cirrhosis[J].Chin J Hepatol,2015,23(10):733-737.(in Chinese)连佳,韩涛,向慧玲,等.恩替卡韦与阿德福韦酯单药治疗慢性乙型肝炎相关性肝病患者240周的随机对照研究[J].中华肝脏病杂志,2015,23(10):733-737.

[6]WIENS A,LENZI L,VENSON R,et al.Comparative efficacy of oral nucleoside or nucleotide analog monotherapy used in chronic hepatitis B:a mixed-treatment comparison meta-analysis[J].Pharmacotherapy,2013,33(2):144-151.

[7]LYU XY,LIU Q,SU JP,et al.Protective effects of Dahuangzhechongwan against rat hepatic fibrosis induced by carbon tetrachloride[J].Lishizhen Med Mater Med Res,2012,23(4):801-802.(in Chinese)吕小燕,刘强,苏娟萍,等.大黄蟅虫丸抗四氯化碳致大鼠肝纤维化的实验研究[J].时珍国医国药,2012,23(4):801-802.

[8]SHI J,TANG HL,CHEN C.Therapeutic efficacy of Dahuang Zhechong pills combined with entecavir in treatment of hepatic fibrosis due to chronic hepatitis B:a report of 20 cases[J].Hunan J Tradit Chin Med,2013,29(5):19-24.(in Chinese)石俊,汤海林,陈超.大黄蟅虫丸联合恩替卡韦治疗慢性乙型肝炎肝纤维化20例[J].湖南中医杂志,2013,29(5):19-24.

[9]GAO YZ,JIA SH,ZHAO LF,et al.Clinical efficacy of entecavir combined with xinganbao capsules in treatment of liver cirrhosis among patients with chronic hepatitis B[J].J Clin Hepatol,2014,30(4):314-316.(in Chinese)高远征,贾素华,赵连峰,等.恩替卡韦联合心肝宝胶囊治疗慢性乙型肝炎肝硬化的疗效观察[J].临床肝胆病杂志,2014,30(4):314-316.

[10]WU G,HE HY,LI Y,et al.Clinical effect of combination therapy with Fufang Biejia Ruangan tablet and entecavir in pafients with hepatitis B virus-related cirrhosis[J].Chin J Hepatol,2014,22(8):604-608.(in Chinese)吴刚,何鸿雁,李烨,等.复方鳖甲软肝片联合恩替卡韦对HBV相关肝硬化患者的临床疗效观察[J].中华肝脏病杂志,2014,22(8):604-608.

[11]JIANG YF,MA J,HE B,et al.The therapeutic effect of Anluohuaxian capsule combined with adefovir dipivoxil on patients with chronic hepatitis B and influence on hepatic histology[J].Chin J Hepatol,2012,20(5):344-347.(in Chinese)蒋永芳,马静,贺波,等.阿德福韦酯联合安络化纤丸治疗慢性乙型肝炎的疗效[J].中华肝脏病杂志,2012,20(5):344-347.

[12]HU GX,WAN ZY,SHAO JL,et al.Effects of hydroxycamptothecin on TGFβ1,α-SMA and collagen I expression in rat hepatic satellite cells[J].Chin J Hepatol,2012,20(6):453-457.(in Chinese)胡国信,万赞燕,邵佳亮,等.羟基喜树碱对大鼠肝星状细胞转化生长因子β1、α-平滑肌肌动蛋白和I型胶原表达的影响[J].中华肝脏病杂志,2012,20(6):453-457.

[13]SHAO JL,HU GX,ZHENG J,et al.Effects of hydroxycamptothecin on hepatic expression of Bax and Bcl-2 genes andα-SMA protein and hepatic fibrosis in rats[J].Acad J Second Military Med Univ,2014,35(4):399-405.(in Chinese)邵佳亮,胡国信,郑洁,等.羟基喜树碱对肝纤维化大鼠肝组织Bax、Bcl-2基因和α-SMA蛋白表达及肝纤维化的影响[J].第二军医大学学报,2014,35(4):399-405.

[14]ZHANG WS,WANG BE,WANG TL,et al.Noninvasive assessment of liver fibrosis in chronic hepatitis B using a predictive model[J].Chin J Hepatol,2006,14(3):169-173.(in Chinese)张文胜,王宝恩,王泰龄,等.慢性乙型肝炎肝纤维化无创性诊断模型的建立[J].中华肝脏病杂志,2006,14(3):169-173.

[15]QIN JH,ZHANG GD,BAI LJ,et al.The diagnostic value of Fibroscan and APRI in liver fibrosis[J/CD].Chin J Liver Dis:Electronic Edition,2015,7(3):106-108.(in Chinese)秦金环,张国栋,白留江,等.Fibroscan与谷草转氨酶-血小板指数(APRI)诊断肝纤维化的价值[J/CD].中国肝脏病杂志:电子版,2015,7(3):106-108.

[16]ZHOU JB.Application of Fibro San combined with other serologic markers on the diagnosis of liver fibrosis[J].Int J Lab Med,2013,34(4):409-411.(in Chinese)周剑波.Fibro Scan联合血清学标志物在肝纤维化诊断中的应用[J].国际检验医学杂志,2013,34(4):409-411.

施引文献

资源附件(0)

访问统计